You are viewing the site in preview mode

Skip to main content

Table 6 Logistic regression analysis for minimum NIC of Grade 0 (Uncoverage) in patients with DM

From: Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation

  Univariate Multivariate
  OR 95% CI p value OR 95% CI p value
Male 1.09 0.39–3.30 1.00    
Age
(1 year increase) 		1.008 098-1.04 0.65    
BMI 1.04 0.96–1.12 0.35    
Hypertension 1.12 0.37–3.38 1.00    
Dyslipidemia 2.01 0.82–5.14 0.14    
Aspirin* – – –    
Clopidogrel* 1.01 0.51–2.02 1.00    
Prasugrel* 1.15 0.58–2.32 0.72    
Ticlopidine* 0.42 0.048–3.71 0.38    
Statin* 2.11 0.94–4.72 0.088 2.44 1.01–5.87 0.047
Insulin, n (%) 0.82 0.32–2.11 0.82    
Biguanide, n (%) 1.43 0.68–3.03 0.44    
DPP-4 inhibitor, n (%) 1.36 0.68–2.74 0.48    
SGLT-2 inhibitor, n (%) 0.53 0.058-4.90 0.50    
Thiazolidine, n (%) 0.82 0.27–2.44 0.79    
Sulfonylurea, n (%) 2.62 1.23–5.57 0.016 3.87 1.66–9.01 0.002
Glinide, n (%) 0.93 0.23–3.75 0.61    
α-glucosidase inhibitor, n (%) 1.78 0.79–4.04 0.19    
Follow-up duration
(1 day increase) 		0.995 0.984–1.007 0.44    
ACS 1.13 0.53–2.37 0.85    
Pre-dilatation balloon maximum diameter
(1 mm increase) 		1.09 0.63–1.90 0.76    
Pre-dilatation balloon maximum inflation pressure
(1 atm increase) 		1.06 0.96–1.16 0.28    
Maximum stent diameter
(1 mm increase) 		1.49 0.69–3.20 0.31    
Minimum stent diameter
(1 mm increase) 		1.13 0.50–2.53 0.77    
Stent implantation pressure
(1 atm increase) 		0.91 0.81–1.02 0.097 0.87 0.76–0.99 0.040
Post-dilatation balloon maximum diameter
(1 mm increase) 		0.86 0.43–1.73 0.67    
Post-dilatation balloon maximum inflation pressure
(1 mm increase) 		0.94 0.84–1.05 0.26    
At the time of PCI       
HbA1c
(1% increase) 		1.07 0.81–1.42 0.65    
FBS
(1 mg/dL increase) 		1.001 0.996–1.007 0.67    
CRP
(1 mg/dL increase) 		1.16 0.84–1.61 0.36    
Total cholesterol
(1 mg/dL increase) 		0.996 0.987–1.005 0.35    
Triglyceride
(1 mg/dL increase) 		1.000 0.997–1.003 0.85    
HDL-cholesterol
(1 mg/dL increase) 		1.022 0.994–1.050 0.12    
LDL-cholesterol
(1 mg/dL increase) 		0.989 0.978-1.000 0.056 0.984 0.972–0.997 0.018
At the time of CAS evaluation       
HbA1c
(1% increase) 		1.23 0.82–1.86 0.32    
FBS
(1 mg/dL increase) 		0.999 0.992–1.005 0.70    
CRP
(1 mg/dL increase) 		0.53 0.18–1.55 0.53    
Total cholesterol
(1 mg/dL increase) 		0.999 0.989–1.009 0.81    
Triglyceride
(1 mg/dL increase) 		1.002 0.999–1.005 0.13    
HDL-cholesterol
(1 mg/dL increase) 		1.001 0.982–1.021 0.91    
LDL-cholesterol
(1 mg/dL increase) 		0.990 0.977–1.004 0.17    
  1. * Medication at the time of CAS evaluation. ACS acute coronary syndrome, BMI  body mass index, CRP C-reactive protein, DM diabetes mellitus, FBS  fasting blood sugar, HbA1c = Hemoglobin A1c, HDL high-density lipoprotein, LDL  low-density lipoprotein
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840